Technical Analysis for FBIO - Fortress Biotech, Inc.

Grade Last Price % Change Price Change
grade B 2.39 -7.00% -0.18
FBIO closed down 7.0 percent on Tuesday, February 25, 2020, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Mar 10
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical FBIO trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -7.00%
MACD Bearish Signal Line Cross Bearish -7.00%
50 DMA Support Bullish -7.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -7.00%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company's principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system's natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. It has strategic alliances and commercial agreements with Ovamed GmbHp; Dr. Falk Pharma GmbH; and Freie Universität Berlin. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in Burlington, Massachusetts.
Medicine Biotechnology Biopharmaceutical Cancer Medical Specialties Clinical Medicine Immunology Immunotherapy Autoimmune Diseases Acute Myeloid Leukemia Ulcerative Colitis Abdominal Pain Crohn's Disease Treatment Of Acute Myeloid Leukemia Treatment Of Autoimmune Diseases

Is FBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.11
52 Week Low 1.2
Average Volume 490,531
200-Day Moving Average 1.83
50-Day Moving Average 2.50
20-Day Moving Average 2.57
10-Day Moving Average 2.71
Average True Range 0.22
ADX 22.67
+DI 20.95
-DI 22.88
Chandelier Exit (Long, 3 ATRs ) 2.46
Chandelier Exit (Short, 3 ATRs ) 2.83
Upper Bollinger Band 2.96
Lower Bollinger Band 2.17
Percent B (%b) 0.28
BandWidth 30.92
MACD Line 0.05
MACD Signal Line 0.08
MACD Histogram -0.025
Fundamentals Value
Market Cap 120.76 Million
Num Shares 50.5 Million
EPS -1.48
Price-to-Earnings (P/E) Ratio -1.61
Price-to-Sales 1.68
Price-to-Book 2.53
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.92
Resistance 3 (R3) 2.95 2.82 2.83
Resistance 2 (R2) 2.82 2.68 2.80 2.80
Resistance 1 (R1) 2.60 2.60 2.54 2.57 2.77
Pivot Point 2.47 2.47 2.43 2.45 2.47
Support 1 (S1) 2.25 2.33 2.19 2.22 2.01
Support 2 (S2) 2.12 2.25 2.10 1.98
Support 3 (S3) 1.90 2.12 1.95
Support 4 (S4) 1.87